NASDAQ:SRPT

Sarepta Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy SRPT

*Your capital is at risk

$17.26

-0.390 (-2.21%)

At Close: Jun 23, 2026

Sarepta Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 75.30. In total, the insiders bought 1.98M and sold 56.24K SRPT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	75.30
● Buy	1.98M shares
● Sell	56.24K shares
71% Buy Activity Strong Negative Correlation
Buy Signal Medium Confidence Jun 22, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 75.3. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 04, 2026 Buy	Common Stock A-Award	Connelly Deirdre P Director	Director	16 875 Value: $281.1K
Jun 04, 2026 Buy	Common Stock A-Award	Behrens M Kathleen Director	Director	16 875 Value: $281.1K
Jun 04, 2026 Buy	Common Stock A-Award	Wigzell Hans Lennart Rudolf Director	Director	16 875 Value: $281.1K
Jun 04, 2026 Buy	Common Stock A-Award	Boor Kathryn Jean Director	Director	16 875 Value: $281.1K
Jun 04, 2026 Buy	Common Stock A-Award	Mayo Stephen Director	Director	16 875 Value: $281.1K
Jun 04, 2026 Buy	Common Stock A-Award	Nicaise Claude Director	Director	16 875 Value: $281.1K
Jun 04, 2026 Buy	Common Stock A-Award	Chambers Michael Andrew Director	Director	16 875 Value: $281.1K
Jun 04, 2026 Buy	Common Stock A-Award	Barry Richard Director	Director	16 875 Value: $281.1K
Mar 12, 2026 Sell	Common Stock S-Sale	Mayo Stephen Director	Director	7 239 Value: $123.2K
Mar 11, 2026 Sell	Common Stock F-InKind	Wong Ryan Ho-yan Chief Financial Officer	C-Suite Officer	256 Value: $4K
Mar 11, 2026 Sell	Common Stock F-InKind	Estepan Ian Michael Chief Operating Officer	C-Suite Officer	1 097 Value: $18.7K
Mar 11, 2026 Sell	Common Stock F-InKind	Rodino-klapac Louise President, R&d And Tech Ops	CEO / President	948 Value: $16.1K
Mar 11, 2026 Sell	Common Stock F-InKind	Rothfuss Cristin EVP, General Counsel	Officer	974 Value: $16.6K
Mar 10, 2026 Buy	Stock Option (Right to buy)	Wong Ryan Ho-yan Chief Financial Officer	C-Suite Officer	1 208 Value: $120.4K
Mar 10, 2026 Buy	Stock Option (Right to buy)	Wong Ryan Ho-yan Chief Financial Officer	C-Suite Officer	1 208 Value: $120.4K
Mar 09, 2026 Sell	Common Stock F-InKind	Rothfuss Cristin EVP, General Counsel	Officer	346 Value: $6K
Mar 09, 2026 Sell	Common Stock F-InKind	Estepan Ian Michael Chief Operating Officer	C-Suite Officer	583 Value: $10K
Mar 09, 2026 Sell	Common Stock F-InKind	Rodino-klapac Louise President, R&d And Tech Ops	CEO / President	504 Value: $9K
Mar 09, 2026 Sell	Common Stock F-InKind	Rothfuss Cristin EVP, General Counsel	Officer	484 Value: $8K
Mar 09, 2026 Sell	Common Stock F-InKind	Wong Ryan Ho-yan Chief Financial Officer	C-Suite Officer	162 Value: $3K
Mar 09, 2026 Sell	Common Stock F-InKind	Estepan Ian Michael Chief Operating Officer	C-Suite Officer	1 036 Value: $17.6K
Mar 09, 2026 Sell	Common Stock F-InKind	Rodino-klapac Louise President, R&d And Tech Ops	CEO / President	895 Value: $15.2K
Mar 09, 2026 Sell	Common Stock F-InKind	Wong Ryan Ho-yan Chief Financial Officer	C-Suite Officer	113 Value: $2K
Mar 02, 2026 Sell	Common Stock F-InKind	Wong Ryan Ho-yan Chief Financial Officer	C-Suite Officer	450 Value: $7K
Mar 02, 2026 Sell	Common Stock F-InKind	Estepan Ian Michael Chief Operating Officer	C-Suite Officer	3 301 Value: $53.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SAREPTA THERAPEUTICS

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of ...

Read Full Profile Here